Ligand Pharmaceuticals (LGND)
122.31
0.31 (0.25%)
At close: Feb 20, 2025, 3:59 PM
122.01
-0.25%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 115.05 |
| Market Cap | 2.31B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 2.5 |
| PE Ratio (ttm) | 48.92 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 123 |
| Volume | 107,127 |
| Avg. Volume (20D) | 103,872 |
| Open | 122.13 |
| Previous Close | 122.00 |
| Day's Range | 120.02 - 122.57 |
| 52-Week Range | 67.72 - 129.90 |
| Beta | undefined |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease ca...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 18, 1992
Employees 58
Stock Exchange NASDAQ
Ticker Symbol LGND
Website https://www.ligand.com
Analyst Forecast
According to 6 analyst ratings, the average rating for LGND stock is "Buy." The 12-month stock price forecast is $141.5, which is an increase of 15.69% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Ligand Pharmaceuticals is scheduled to release its earnings on Feb 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+11.12%
Ligand Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
